ClinicalTrials.gg
TerminatedNCT04757857CAREUpdated Jan 25, 2023

COVID-19 Antithrombotic Rivaroxaban Evaluation

A Phase 4 interventional study of Rivaroxaban 10 mg in COVID-19, sponsored by Hospital Alemão Oswaldo Cruz. Terminated at 36 sites in Brazil. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-01-25.

Sponsored by Hospital Alemão Oswaldo Cruz · Phase 4, Interventional, and Treatment

How we know

Why this study was terminated
Sustained reduction in the number of new COVID-19 cases as well as lower than expected event rates

From the registry’s dates

  • Registered 4 months after the study started (first participant enrolled Sep 2020, registered Feb 2021).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
660
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 11 studies testing rivaroxaban in COVID-19 — none open to participants now, none under way, none of them phase 3. Rivaroxaban · COVID-19.

Enrollment
3rd of 11
660 · median 497
Started
2020
with 10 others
Phase 4
3 of 11
none open now
Registered
11th of 11
by date
Lead sponsor
1 of 11
Hospital Alemão Oswaldo Cruz

Among the 11 studies testing rivaroxaban in COVID-19, this one is the 3rd largest by enrollment, is one of 11 that started in 2020, is one of 3 in phase 4, and was the 11th registered.

COVID-19

7,996 studies on the registry are indexed under COVID-19; 469 are open to participants now.

Browse COVID-19 studies →

Open to participants now

None of the 11 studies testing rivaroxaban in COVID-19 is open now. The open studies under COVID-19, anywhere →

About rivaroxaban

Rivaroxaban: first FDA approval 2011 (XARELTO), first EMA approval 2008. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 356 COVID-19 studies recruiting now, 205 (58%) set no upper age limit and 84 (24%) stop at 75 or younger; 90 take children under 18; 135 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 11 studies testing rivaroxaban in COVID-19 as a file.
02

Study summary

There are several ways in which the COVID-19 pandemic may affect the prevention and management of thrombotic and thromboembolic disease, either direct effect or the indirect effects of infection, such as through severe illness and hypoxia, may predispose patients to thrombotic events. The severe inflammatory response, critical illness, and underlying traditional risk factors may all predispose to thrombotic events. Therefore, considering the high-risk profile of cardiovascular comorbidities in patients with COVID-19, it is scientifically relevant to evaluate the use of anticoagulants as an adjunctive treatment in the context of COVID-19. Indeed, it will be tested the hypothesis that the use of moderate dose of rivaroxaban has a beneficial effect in the treatment of patients with a confirmed or probable diagnosis of COVID-19 infection, with no clear indication for hospitalization (mild and moderate cases) upon initial medical care, by reducing the need of hospitalization due to complications related to COVID-19.

Read the detailed description

Initial studies suggest an inflammatory state and hypercoagulation in individuals with COVID-19. Apparently, the fact that the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein binds to Angiotensin Converting Enzyme 2 (ACE2) receptors can lead to ACE2 depletion by SARS-CoV-2 favoring the "harmful" ACE1 / angiotensin II and promoting tissue damage, including stroke. Recent observational studies indicate a higher rate of thromboembolism in patients with COVID-19, especially those in severe condition. They also report that, in patients treated with anticoagulants, complication rates were lower as compared with those not receiving anticoagulant therapies.

More recently, in a post-mortem study of patients with Covid-19 compared to recently published cases of influenza, the histopathological pattern on the periphery of the lungs of patients with Covid-19 revealed a diffuse alveolar lesion with infiltration of perivascular T cells and other vascular aspects, consisting of severe endothelial damage (endothelitis) associated with the presence of intracellular viruses and broken cell membranes. In addition, pulmonary vessels showed generalized thrombosis with microangiopathy, and alveolar capillary microthrombi were much more frequent in patients with COVID-19 than with severe influenza respiratory conditions.

03

Conditions studied

  • COVID-19

Browse trials for

Keywords

  • SARS-Cov-2
  • COVID-19
  • Rivaroxaban
  • Antithrombotic
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Adults ≥ 18 years old;
  2. Evaluated in the emergency unit with probable or confirmed infection by COVID-19;
  3. Time between symptoms and inclusion ≤ 07 days *;
  4. Present mild or moderate signs and symptoms, with no clear indication for hospitalization;
  5. Present at least 2 risk factors for complication:

    • 65 years
    • Hypertension
    • Diabetes mellitus
    • Asthma
    • (COPD) or other chronic lung diseases
    • Smoking
    • Obesity (> 30)
    • History of non-active cancer
    • Bed restriction or reduced mobility (≥50% of the wake time without walking)
    • Previous history of VTE
    • Use of oral hormonal

Exclusion criteria

Exclusion Criteria:

  1. Patients \<18 years old;
  2. Hospitalization indication upon first medical care;
  3. Positive test for influenza in the first visit;
  4. Any known liver disease associated with coagulopathy; (International Normalized Ratio) > 1.5;
  5. Pregnant, lactating or with the possibility of becoming pregnant and without using an adequate method;
  6. High risk of bleeding; History of bronchiectasis or pulmonary cavitation, Significant bleeding in the last 3 months, Active gastroduodenal ulcer, history of recent bleeding (within 3 months) or a high risk of bleeding;
  7. Stroke within 1 month or any history of hemorrhagic or lacunar stroke or any intracranial bleeding or any intracranial neoplasia, , arteriovenous malformation or brain aneurysm;
  8. Severe heart failure with \<30% (echocardiogram or other validated method previously documented) or symptoms of heart failure class III or IV of the (NYHA);
  9. Estimated (eGFR) \<30 mL / min;
  10. Clinical indication for dual antiplatelet therapy or anticoagulation therapy (VTE, atrial fibrillation / flutter, mechanical valve prosthesis);
  11. Marked thrombocytopenia ( \<50,000 / mm3);
  12. Non-cardiovascular disease that is associated with a poor prognosis, for example, active cancer (excluding non-melanoma skin cancer) defined as cancer without remission or requiring active chemotherapy or therapies such as immunotherapy or radiation therapy or that increases the risk of an adverse reaction to the evaluated interventions;
  13. History of or known to rivaroxaban;
  14. Systemic treatment with strong inhibitors of Cytochrome P450 3A4 () and glycoprotein p (Pgp) (for example, systemic azole antimycotics, such as ketoconazole and [HIV] protein inhibitors, such as ritonavir) or strong inducers of CYP 3A4, that is, rifampicin, rifabutin, phenobarbital, phenytoin and carbamazepine;
  15. Current treatment being tested;
  16. Concomitant participation in another study with experimental drugs in the context of COVID;
  17. Use of chloroquine or hydroxychloroquine associated with azithromycin;
  18. Active cancer;
  19. Other contraindications to rivaroxaban;
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
660 participants (actual)

Study arms

  • Active comparator
    Rivaroxaban 10 mg

    Participants will receive, from the 1st to the 14th day, a dose of 10 mg of rivaroxaban - OA (Oral Administration).

    Drug: Rivaroxaban 10 mg

  • No intervention
    Best locally standardized care

    According to the study protocol, participating investigators are advised to follow the best available local practice in each participating site. There is no formal recommendation for any particular COVID-19 treatment, except symptomatic therapies.

Interventions

06

What researchers measure

Primary outcomes

  1. Venous thromboembolic events (VTE)

    Defined as deep venous thrombosis, acute pulmonary embolism, other major venous thrombotic events.

    Time frame: Within 30 days from randomization

  2. Mechanical ventilation free-survival

    Defined as survival without requirement of mechanical ventilation.

    Time frame: Within 30 days from randomization

  3. Major Adverse Cardiovascular Events (MACE)

    Defined as acute myocardial infarction, stroke or acute limb ischemia

    Time frame: Within 30 days from randomization

  4. Out-of-hospital death not attributed to major injury

    Death that occurred out of hospital due to any cause not related to trauma or other major injury

    Time frame: Within 30 days from randomization

Secondary outcomes

  1. Time from randomization to hospitalization

    Defined as time elapsed since randomization to hospital admission

    Time frame: 30 days from randomization

  2. Length of Hospitalization

    To assess the duration of hospitalization (length of hospital stay)

    Time frame: 30 days from randomization

  3. Hospitalization in Intensive Care Unit

    Requirement of admission to ICU for intensive care

    Time frame: 30 days from randomization

  4. Clinical requirement of mechanical ventilation

    Requirement of oxygen supplementation through invasive or non invasive mechanical ventilation.

    Time frame: 30 days from randomization

  5. Clinical duration of mechanical ventilation

    Total time on oxygen supplementation through invasive or non invasive mechanical ventilation

    Time frame: 30 days from randomization

  6. Composite vascular endpoint I

    Non-fatal myocardial infarction, non-fatal ischemic stroke or cardiovascular death, VTE

    Time frame: 30 days from randomization

  7. Composite vascular endpoint II

    Cardiovascular death, non-fatal myocardial infarction, non-fatal ischemic stroke or acute limb ischemia, VTE

    Time frame: 30 days from randomization

  8. Major Bleeding

    Defined by International Society of Thrombosis and Hemostasis (ISTH) criteria

    Time frame: 30 days from randomization

  9. Mortality

    Defined by all-cause deaths

    Time frame: 30 days from randomization

07

Study locations

36 sites
  • Clínica Senhor do Bonfim
    Feira de Santana, Bahia, Brazil
  • Hospital Maternidade São Vicente de Paulo
    Barbalha, Ceará, Brazil
  • Hospital de Base do Distrito Federal
    Brasília, Distrito Federal, Brazil
  • Hospital de Campanha Covid-19 Goiânia/Sesgo
    Goiânia, Goias, Brazil
  • Hospital Estadual de Urgências de Trindade/SESGO
    Trindade, Goias, Brazil
  • Núcleo de Pesquisa Clínica do Hospital Vera Cruz
    Belo Horizonte, Minas Gerais 30190-130, Brazil
  • Hospital São Lucas
    Belo Horizonte, Minas Gerais, Brazil
  • Santa Casa de Misericórdia de Passos
    Passos, Minas Gerais, Brazil
  • Hospital Universitário Regional de Maringá
    Maringá, Paraná, Brazil
  • Beneficencia Nipo Brasileira Da Amazonia
    Belém, Para 66060-575, Brazil
  • Hospital Adventista de Belém
    Belém, Para 66093-904, Brazil
  • Associação Dr. Bartholomeu Tacchini
    Bento Gonçalves, Rio Grande Do Sul, Brazil
  • Hospital São Vicente de Paulo
    Passo Fundo, Rio Grande Do Sul 99010-080, Brazil
  • Hospital das Clínicas de Porto Alegre
    Porto Alegre, Rio Grande Do Sul, Brazil
  • Hospital Universitario de Santa Maria
    Santa Maria, Rio Grande Do Sul 97900015, Brazil
  • Clínica Procárdio Ltda
    Blumenau, Santa Catarina, Brazil
  • H&W Cardiologia LTDA
    Joinville, Santa Catarina 89204-250, Brazil
  • Irmandade santa Casa de Araras
    Araras, São Paulo 13600-655, Brazil
  • Alphacor Cardiologia Clínica e Diagnóstica LTDA
    Barueri, São Paulo, Brazil
  • Maestri e Kormann Consultoria Medico-Cientifica LTDA - EPP
    Blumenau, São Paulo, Brazil
  • Hospital Regional do Litoral Norte - Instituto Sócrates Guanaes
    Caraguatatuba, São Paulo, Brazil
  • Hospital Santos Dumont Litoral Norte
    Caraguatatuba, São Paulo, Brazil
  • Hospital de Corderiopolis
    Cordeiropolis, São Paulo, Brazil
  • Hospital Regional Jorge Rossman - Instituto Sócrates Guanaes
    Itanhaém, São Paulo, Brazil
  • Hospital Carlos Fernando Malzoni
    Matão, São Paulo, Brazil
  • Hospital Moinhos de Vento
    Porto Alegre, São Paulo 90035-001, Brazil
  • Hospital Regional de Registro - Instituto Sócrates Guanaes
    Registro, São Paulo, Brazil
  • Hospital Unimed Ribeirão Preto
    Ribeirão Preto, São Paulo, Brazil
  • Kaiser Clinica e Hospital Dia
    São José do Rio Preto, São Paulo 15015-110, Brazil
  • Braile Hospital Dia Ltda
    São José Do Rio Preto, São Paulo, Brazil
  • Hospital Policlin
    São José Dos Campos, São Paulo 12 243 000, Brazil
  • Hospital Regional de São José dos Campos - Instituto Sócrates Guanaes
    São José Dos Campos, São Paulo, Brazil
  • Santa Casa de Misericórdia de Votuporanga
    Votuporanga, São Paulo, Brazil
  • International Research Center - Hospital Alemão Oswaldo Cruz
    São Paulo, 01323-903, Brazil
  • Hospital Leforte Liberdade
    São Paulo, 01506-000, Brazil
  • Incor - Instituto do Coração do Hospital das Clínicas da FMUSP
    São Paulo, 05403-010, Brazil
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Sep 2020 to primary completion in Aug 2022, 22 months.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 8, 2021
First posted
Feb 17, 2021
StartActual
Sep 29, 2020
Primary completionActual
Aug 8, 2022
CompletionActual
Aug 30, 2022
Last update
Jan 25, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 25, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04757857
Lead sponsor
Hospital Alemão Oswaldo Cruz
Collaborators
Bayer, Hospital Israelita Albert Einstein, Hospital do Coracao, Hospital Sirio-Libanes, Hospital Moinhos de Vento, Brazilian Research In Intensive Care Network, Brazilian Clinical Research Institute
Responsible party
Álvaro Avezum Junior (Research Manager - International Research Center, Hospital Alemão Oswaldo Cruz) — Principal investigator
First posted
Feb 17, 2021
Start date
Sep 29, 2020
Primary completion
Aug 8, 2022
Completion
Aug 30, 2022
Last update
Jan 25, 2023

Study contacts

Álvaro Avezum, Ph.D
principal investigator · International Research Center - Hospital Alemão Oswaldo Cruz

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jan 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Rivaroxaban

Start the discussion